Daniel Giang is a Neurology physician affiliated with Loma Linda University. OpenAlex indexes 24 publications with 848 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11370 Anderson St
Suite 2400
Loma Linda, CA 923543450
Telephone
909-558-2880Provider last certified this registry record 23 Mar 2022.
Clinical trials
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Sponsor: Acorda Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20242 payments
- ABBVIE INC.Program year20241 payment
- Travere Therapeutics, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Potassium Channel Blocker35.3%Dalfampridine Er100%Part D<11 patientsGabapentinoids27.1%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- UGRC 2021 recommendations on GME transition: pros and cons, opportunities and limitations
Journal of Osteopathic Medicine
2022 - Medical Student Performance Evaluation (MSPE) 2017 Task Force Recommendations as Reflected in the Format of 2018 MSPE
Journal of Graduate Medical Education
2019 - Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
Neurology Clinical Practice
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Latika Puri, MD
Loma Linda University
Gary Fraser, MD
Loma Linda University
Feng Yan
Loma Linda University
Reinhard Schulte, MD
Loma Linda University
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”